# Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer

> **NCT07528209** · PHASE3 · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 556 (estimated)

## Conditions studied

- Rectal Cancer
- pMMR (Microsatellite Stable Rectal Cancer)

## Interventions

- **DRUG:** Pucotenlimab combine with CAPOX
- **DRUG:** CAPOX

## Key facts

- **NCT ID:** NCT07528209
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-20
- **Primary completion:** 2032-04-20
- **Final completion:** 2034-04-20
- **Target enrollment:** 556 (ESTIMATED)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07528209

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07528209, "Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07528209. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*